Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine

被引：18

作者：

Baldanti, F ^{[1
]}

Paolucci, S

Maga, G

Labo, N

Hübscher, U

Skoblov, AY

Victorova, L

Spadari, S

Minoli, L

Gerna, G

机构：

[1] IRCCS, Policlin San Matteo, Serv Virol, Pavia, Italy

[2] CNR, Ist Genet Mol, Pavia, Italy

[3] Univ Zurich, Inst Vet Biochem & Mol Biol, Zurich, Switzerland

[4] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia

[5] Univ Pavia, Ist Clin Malattie Infett, Pavia, Italy

来源：

AIDS | 2003年 / 17卷 / 10期

关键词：

D O I：

10.1097/00002030-200307040-00021

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.

引用

页码：1568 / 1570

页数：3

共 6 条

[1] Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay [J].